Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies
Abstract
:Simple Summary
Abstract
1. Background
2. Salvage Surgery in Patients with Recurrent/Metastatic Disease
3. The Evolving Role of Re-Irradiation (Curative or Palliative Intent)
3.1. Introduction
3.2. RT Schemes Employed in the Clinical Practice for Recurrent/Metastatic Disease
3.3. Palliative Schemes
3.4. Curative Schemes
3.5. The Abscopal Effect
4. Post-Operative Re-Irradiation (+/− Chemotherapy)
5. The Role of Electrochemotherapy
6. The Role of Systemic Strategies (Chemo and Immunotherapy)
7. The Role of Metastasis Directed Therapy (MTD)
8. Discussion and Conclusions
Funding
Conflicts of Interest
References
- Stenson, K.M. Epidemiology and Risk Factors for Head and Neck Cancer. 2019. Available online: https://www.uptodate.com/contents/epidemiology-andrisk-factors-for-head-and-neck-cancer (accessed on 21 March 2021).
- Gillison, M.L.; Chaturvedi, A.K.; Anderson, W.F.; Fakhry, C. Epidemiology of Human Papillomavirus–Positive Head and Neck Squamous Cell Carcinoma. J. Clin. Oncol. 2015, 33, 3235–3242. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- NCCN Guidelines Version 1. Head and Neck Cancer. 2021. Available online: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (accessed on 21 March 2021).
- Pignon, J.-P.; le Maître, A.; Maillard, E.; Bourhis, J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 2009, 92, 4–14. [Google Scholar] [CrossRef] [PubMed]
- Muzaffar, J.; Bari, S.; Kirtane, K.; Chung, C. Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. Cancers 2021, 13, 338. [Google Scholar] [CrossRef] [PubMed]
- Samra, B.; Tam, E.; Baseri, B.; Shapira, I. Checkpoint inhibitors in head and neck cancer: Current knowledge and perspectives. J. Investig. Med. 2018, 66, 1023–1030. [Google Scholar] [CrossRef] [Green Version]
- Temam, S.; Pape, E.; Janot, F.; Wibault, P.; Julieron, M.; Lusinchi, A.; Mamelle, G.; Marandas, P.; Luboinski, B.; Bourhis, J. Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. 2005, 62, 1078–1083. [Google Scholar] [CrossRef]
- Zafereo, M.E.; Hanasono, M.M.; Rosenthal, D.I.; Sturgis, E.M.; Lewin, J.S.; Roberts, D.B.; Weber, R.S. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer 2009, 115, 5723–5733. [Google Scholar] [CrossRef]
- Matoscevic, K.; Graf, N.; Pezier, T.; Huber, G. Success of salvage treatment: A critical appraisal of salvage rates for different subsites of HNSCC. Otolaryngol. Head Neck Surg. 2014, 151, 454–461. [Google Scholar] [CrossRef]
- Elbers, J.B.W.; Al-Mamgani, A.; Brekel, M.W.M.V.D.; Jóźwiak, K.; De Boer, J.P.; Lohuis, P.J.F.M.; Willems, S.M.; Verheij, M.; Zuur, C.L. Salvage Surgery for Recurrence after Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. Otolaryngol. Neck Surg. 2018, 160, 1023–1033. [Google Scholar] [CrossRef]
- Narvaez, C.; Schild, S.E.; Rades, D. Comparison of Conventional Fractionation and Accelerated Fractionation with Concomitant Boost for Radiotherapy of Non-metastatic Stage IV Head-and-Neck Cancer. Vivo 2021, 35, 411–415. [Google Scholar] [CrossRef]
- Xiang, M.; Gensheimer, M.F.; Pollom, E.L.; Holsinger, F.C.; Colevas, A.D.; Le, Q.-T.; Beadle, B.M. Prolongation of definitive head and neck cancer radiotherapy: Survival impact and predisposing factors. Radiother. Oncol. 2020, 156, 201–208. [Google Scholar] [CrossRef]
- García-Consuegra, A.; Morales, M.G.; Cambeiro, M.; Tagliaferri, L.; Kovacs, G.; Van Limbergen, E.; Ramos, L.I.; Arnaiz, J.M.; Alcalde, J.; Lecanda, F.; et al. Dose volume histogram constraints in patients with head and neck cancer treated with surgery and adjuvant HDR brachytherapy: A proposal of the head and neck and skin GEC ESTRO Working group. Radiother. Oncol. 2021, 154, 128–134. [Google Scholar] [CrossRef]
- Lapeyre, M.; Biau, J.; Miroir, J.; Moreau, J.; Gleyzolle, B.; Brun, L.; Racadot, S.; Graff-Cailleaud, P. Concurrent chemoradiotherapy for head neck cancers. Should organs at risk dose constraints be revisited? Cancer Radiother. 2020, 24, 586–593. [Google Scholar] [CrossRef]
- Inal, A.; Duman, E.; Ozkan, E. Evaluating different radiotherapy treatment plans, in terms of critical organ scoring index, conformity index, tumor control probability, and normal tissue complication probability calculations in early glottic larynx carcinoma. J. Cancer Res. Ther. 2020, 16, 485. [Google Scholar] [CrossRef]
- Vargo, J.A.; Ward, M.C.; Caudell, J.J.; Riaz, N.; Dunlap, N.E.; Isrow, D.; Zakem, S.J.; Dault, J.; Awan, M.J.; Higgins, K.A.; et al. A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer. Int. J. Radiat. Oncol. 2018, 100, 595–605. [Google Scholar] [CrossRef]
- Sulman, E.P.; Schwartz, D.L.; Le, T.T.; Ang, K.K.; Morrison, W.H.; Rosenthal, D.I.; Ahamad, A.; Kies, M.; Glisson, B.; Weber, R.; et al. IMRT Reirradiation of Head and Neck Cancer—Disease Control and Morbidity Outcomes. Int. J. Radiat. Oncol. 2009, 73, 399–409. [Google Scholar] [CrossRef]
- Ho, J.C.; Phan, J. Reirradiation of head and neck cancer using modern highly conformal techniques. Head Neck 2018, 40, 2078–2093. [Google Scholar] [CrossRef]
- Paleri, V.; Kelly, C. Re-irradiation with concurrent chemotherapy in recurrent head and neck cancer: A decision analysis model based on a systematic review. Clin. Otolaryngol. 2008, 33, 331–337. [Google Scholar] [CrossRef]
- Anand, A.K.; Dua, B.; Bansal, A.K.; Singh, H.M.; Verma, A.; Kumar, A. Stereotactic ablative radiotherapy (SABR) for recurrent and previously irradiated head and neck cancers. BJR Open 2020, 2, 20190051. [Google Scholar] [CrossRef]
- Lee, J.; Kim, T.H.; Kim, Y.-S.; Kim, M.; Park, J.W.; Kim, S.H.; Kim, H.J.; Lee, C.G. Intensity-Modulated Radiotherapy-Based Reirradiation for Head and Neck Cancer: A Multi-institutional Study by Korean Radiation Oncology Group (KROG 1707). Cancer Res. Treat. 2020, 52, 1031–1040. [Google Scholar] [CrossRef]
- Lee, J.; Shin, I.; Kim, W.C.; Yoon, W.S.; Koom, W.S.; Rim, C.H. Reirradiation with intensity-modulated radiation therapy for recurrent or secondary head and neck cancer: Meta-analysis and systematic review. Head Neck 2020, 42, 2473–2485. [Google Scholar] [CrossRef]
- Gogineni, E.; Zhang, I.; Rana, Z.; Marrero, M.; Gill, G.; Sharma, A.; Riegel, A.C.; Teckie, S.; Ghaly, M. Quality of Life Outcomes Following Organ-Sparing SBRT in Previously Irradiated Recurrent Head and Neck Cancer. Front. Oncol. 2019, 9, 836. [Google Scholar] [CrossRef] [Green Version]
- Rwigema, J.-C.M.; Heron, D.E.; Ferris, R.L.; Andrade, R.S.; Gibson, M.K.; Yang, Y.; Ozhasoglu, C.; Argiris, A.E.; Grandis, J.R.; Burton, S.A. The Impact of Tumor Volume and Radiotherapy Dose on Outcome in Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck Treated with Stereotactic Body Radiation Therapy. Am. J. Clin. Oncol. 2011, 34, 372–379. [Google Scholar] [CrossRef] [Green Version]
- Mohanti, B.K.; Umapathy, H.; Bahadur, S.; Thakar, A.; Pathy, S. Short course palliative radiotherapy of 20Gy in 5 fractions for advanced and incurable head and neck cancer: AIIMS study. Radiother. Oncol. 2004, 71, 275–280. [Google Scholar] [CrossRef]
- Stevens, C.M.; Huang, S.H.; Fung, S.; Bayley, A.J.; Cho, J.B.; Cummings, B.J.; Dawson, L.A.; Hope, A.J.; Kim, J.J.; O’Sullivan, B.; et al. Retrospective Study of Palliative Radiotherapy in Newly Diagnosed Head and Neck Carcinoma. Int. J. Radiat. Oncol. 2011, 81, 958–963. [Google Scholar] [CrossRef]
- Corry, J.; Peters, L.J.; Costa, I.D.; Milner, A.D.; Fawns, H.; Rischin, D.; Porceddu, S. The ‘QUAD SHOT’—A phase II study of palliative radiotherapy for incurable head and neck cancer. Radiother. Oncol. 2005, 77, 137–142. [Google Scholar] [CrossRef] [PubMed]
- Porceddu, S.V.; Rosser, B.; Burmeister, B.; Jones, M.; Hickey, B.; Baumann, K.; Gogna, K.; Pullar, A.; Poulsen, M.; Holt, T. Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment—“Hypo Trial” authors letter of reply. Radiother. Oncol. 2008, 87, 309. [Google Scholar] [CrossRef]
- Iqbal, M.S.; West, N.; Richmond, N.; Kovarik, J.; Gray, I.; Willis, N.; Morgan, D.; Yazici, G.; Cengiz, M.; Paleri, V.; et al. A systematic review and practical considerations of stereotactic body radiotherapy in the treatment of head and neck cancer. Br. J. Radiol. 2021, 94. [Google Scholar] [CrossRef]
- Baliga, S.; Kabarriti, R.; Ohri, N.; Haynes–Lewis, H.; Yaparpalvi, R.; Kalnicki, S.; Garg, M.K. Stereotactic body radiotherapy for recurrent head and neck cancer: A critical review. Head Neck 2016, 39, 595–601. [Google Scholar] [CrossRef]
- Rühle, A.; Sprave, T.; Kalckreuth, T.; Stoian, R.; Haehl, E.; Zamboglou, C.; Laszig, R.; Knopf, A.; Grosu, A.-L.; Nicolay, N.H. The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer. Radiat. Oncol. 2020, 15, 1–13. [Google Scholar] [CrossRef] [PubMed]
- Caudell, J.J.; Ward, M.C.; Riaz, N.; Zakem, S.J.; Awan, M.J.; Dunlap, N.E.; Isrow, D.; Hassanzadeh, C.; Vargo, J.A.; Heron, D.E.; et al. Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis. Int. J. Radiat. Oncol. 2018, 100, 606–617. [Google Scholar] [CrossRef] [PubMed]
- Al-Mayah, A.; Bright, S.; Chapman, K.; Irons, S.; Luo, P.; Carter, D.; Goodwin, E.; Kadhim, M. The non-targeted effects of radiation are perpetuated by exosomes. Mutat. Res. Mol. Mech. Mutagen. 2015, 772, 38–45. [Google Scholar] [CrossRef] [PubMed]
- Jella, K.K.; Rani, S.; O’Driscoll, L.; McClean, B.; Byrne, H.J.; Lyng, F.M. Exosomes Are Involved in Mediating Radiation Induced Bystander Signaling in Human Keratinocyte Cells. Radiat. Res. 2014, 181, 138–145. [Google Scholar] [CrossRef]
- Formenti, S.C.; Demaria, S. Systemic effects of local radiotherapy. Lancet Oncol. 2009, 10, 718–726. [Google Scholar] [CrossRef] [Green Version]
- Galluzzi, L.; Buqué, A.; Kepp, O.; Zitvogel, L.; Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 2017, 17, 97–111. [Google Scholar] [CrossRef]
- Pandolfi, F.; Altamura, S.; Frosali, S.; Conti, P. Key Role of DAMP in Inflammation, Cancer, and Tissue Repair. Clin. Ther. 2016, 38, 1017–1028. [Google Scholar] [CrossRef] [Green Version]
- Kono, H.; Rock, K.L. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 2008, 8, 279–289. [Google Scholar] [CrossRef]
- Vanpouille-Box, C.; Alard, A.; Aryankalayil, M.J.; Sarfraz, Y.; Diamond, J.M.; Schneider, R.J.; Inghirami, G.; Coleman, C.N.; Formenti, S.C.; DeMaria, S. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 2017, 8, 15618. [Google Scholar] [CrossRef]
- Dewan, M.Z.; Galloway, A.E.; Kawashima, N.; Dewyngaert, J.K.; Babb, J.S.; Formenti, S.C.; Demaria, S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 2009, 15, 5379–5388. [Google Scholar] [CrossRef] [Green Version]
- Portella, L.; Scala, S. Ionizing radiation effects on the tumor microenvironment. Semin. Oncol. 2019, 46, 254–260. [Google Scholar] [CrossRef]
- Vereecque, R.; Buffenoir, G.; Gonzalez, R.; Cambier, N.; Hetuin, D.; Bauters, F.; Fenaux, P.; Quesnel, B. γ-Ray irradiation induces B7.1 expression in myeloid leukaemic cells. Br. J. Haematol. 2000, 108, 825–831. [Google Scholar] [CrossRef]
- Vondrácek, J.; A Sheard, M.; Krejcí, P.; Minksová, K.; Hofmanová, J.; Kozubík, A. Modulation of death receptor-mediated apoptosis in differentiating human myeloid leukemia HL-60 cells. J. Leukoc. Biol. 2001, 69, 794–802. [Google Scholar]
- Kalbasi, A.; June, C.H.; Haas, N.; Vapiwala, N. Radiation and immunotherapy: A synergistic combination. J. Clin. Investig. 2013, 123, 2756–2763. [Google Scholar] [CrossRef]
- Golden, E.B.; Epellicciotta, I.; Edemaria, S.; Ebarcellos-Hoff, M.H.; Formenti, S.C. The convergence of radiation and immunogenic cell death signaling pathways. Front. Oncol. 2012, 2, 88. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Buchwald, Z.S.; Efstathiou, J.A. Immunotherapy and Radiation—A New Combined Treatment Approach for Bladder Cancer? Bladder Cancer 2015, 1, 15–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Buchwald, Z.S.; Wynne, J.; Nasti, T.H.; Zhu, S.; Mourad, W.F.; Yan, W.; Gupta, S.; Khleif, S.N.; Khan, M.K. Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation. Front. Oncol. 2018, 8, 612. [Google Scholar] [CrossRef] [PubMed]
- Singh, C.; Qian, J.M.; Yu, J.B.; Chiang, V.L. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non–small cell lung cancer with brain metastases. J. Neurosurg. 2020, 132, 512–517. [Google Scholar] [CrossRef] [PubMed]
- Menon, H.; Chen, D.; Ramapriyan, R.; Verma, V.; Barsoumian, H.B.; Cushman, T.R.; Younes, A.I.; Cortez, M.A.; Erasmus, J.J.; De Groot, P.; et al. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J. Immunother. Cancer 2019, 7, 237. [Google Scholar] [CrossRef] [Green Version]
- McBride, S.; Sherman, E.; Tsai, C.J.; Baxi, S.; Aghalar, J.; Eng, J.; Zhi, W.I.; McFarland, D.; Michel, L.S.; Young, R.; et al. Randomized Phase II Trial of Nivolumab with Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. J. Clin. Oncol. 2021, 39, 30–37. [Google Scholar] [CrossRef]
- Babiker, H.M.; Brana, I.; Mahadevan, D.; Owonikoko, T.K.; Calvo, E.; Rischin, D.; Moreno, V.; Papadopoulos, K.P.; Crittenden, M.; Formenti, S.; et al. Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ann. Oncol. 2018, 29, X27. [Google Scholar] [CrossRef]
- Janot, F.; De Raucourt, D.; Benhamou, E.; Ferron, C.; Dolivet, G.; Bensadoun, R.-J.; Hamoir, M.; Géry, B.; Julieron, M.; Castaing, M.; et al. Randomized Trial of Postoperative Reirradiation Combined with Chemotherapy After Salvage Surgery Compared with Salvage Surgery Alone in Head and Neck Carcinoma. J. Clin. Oncol. 2008, 26, 5518–5523. [Google Scholar] [CrossRef]
- Vargo, J.A.; Heron, D.E.; Ferris, R.L.; Rwigema, J.-C.M.; Wegner, R.E.; Kalash, R.; Ohr, J.; Kubicek, G.J.; Burton, S. Prospective evaluation of patient-reported quality-of-life outcomes following SBRT±cetuximab for locally-recurrent, previously-irradiated head and neck cancer. Radiother. Oncol. 2012, 104, 91–95. [Google Scholar] [CrossRef]
- Takiar, V.; Garden, A.S.; Ma, D.; Morrison, W.H.; Edson, M.; Zafereo, M.E.; Gunn, G.B.; Fuller, C.D.; Beadle, B.; Frank, S.J.; et al. Reirradiation of Head and Neck Cancers with Intensity Modulated Radiation Therapy: Outcomes and Analyses. Int. J. Radiat. Oncol. 2016, 95, 1117–1131. [Google Scholar] [CrossRef]
- Clover, A.; De Terlizzi, F.; Bertino, G.; Curatolo, P.; Odili, J.; Campana, L.; Kunte, C.; Muir, T.; Brizio, M.; Sersa, G.; et al. Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008–2019). Eur. J. Cancer 2020, 138, 30–40. [Google Scholar] [CrossRef]
- De Bree, R.; Wessel, I. Electrochemotherapy in the head and neck area: An addition to the treatment armamentarium. Curr. Opin. Otolaryngol. Head Neck Surg. 2020, 28, 112–117. [Google Scholar] [CrossRef]
- Bertino, G.; Sersa, G.; De Terlizzi, F.; Occhini, A.; Plaschke, C.C.; Groselj, A.; Langdon, C.; Grau, J.J.; McCaul, J.A.; Heuveling, D.; et al. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer. Eur. J. Cancer 2016, 63, 41–52. [Google Scholar] [CrossRef] [Green Version]
- Longo, F.; Perri, F.; Caponigro, F.; Scarpati, G.D.V.; Guida, A.; Pavone, E.; Aversa, C.; Muto, P.; Giuliano, M.; Ionna, F.; et al. Boosting the Immune Response with the Combination of Electrochemotherapy and Immunotherapy: A New Weapon for Squamous Cell Carcinoma of the Head and Neck? Cancers 2020, 12, 2781. [Google Scholar] [CrossRef]
- Tremble, L.F.; O’Brien, M.A.; Soden, D.M.; Forde, P.F. Electrochemotherapy with cisplatin increases survival and induces immunogenic responses in murine models of lung cancer and colorectal cancer. Cancer Lett. 2019, 442, 475–482. [Google Scholar] [CrossRef]
- Baues, C.; Schlaak, M.; von Bergwelt-Baildon, M.; Theurich, S. Should we be combining local tumor therapies with immunotherapies as standard? Future Oncol. 2017, 13, 1573–1575. [Google Scholar] [CrossRef]
- Longo, F.; Perri, F.; Pavone, E.; Aversa, C.; Maglione, M.G.; Guida, A.; Montano, M.; Villano, S.; Daponte, A.; Caponigro, F.; et al. Electrochemotherapy as palliative treatment in patients with advanced head and neck tumours: Outcome analysis in 93 patients treated in a single institution. Oral Oncol. 2019, 92, 77–84. [Google Scholar] [CrossRef]
- Plaschke, C.C.; Bertino, G.; McCaul, J.A.; Grau, J.J.; de Bree, R.; Sersa, G.; Occhini, A.; Groselj, A.; Langdon, C.; Heuveling, D.A.; et al. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers. Eur. J. Cancer 2017, 87, 172–181. [Google Scholar] [CrossRef]
- Bonadies, A.; Bertozzi, E.; Cristiani, R.; Govoni, F.; Migliano, E. Electrochemotherapy in Skin Malignancies of Head and Neck Cancer Patients: Clinical Efficacy and Aesthetic Benefits. Acta Derm. Venereol. 2019, 99, 1246–1252. [Google Scholar] [CrossRef]
- Nishio, M.; Kagami, Y.; Narimatsu, N.; Asano, K.; Sanbe, S.; Somekawa, Y. Treatment of squamous cell carcinoma of the head and neck with multi-drug chemotherapy and radiotherapy. Gan Kagaku Ryoho. Cancer Chemother. 1989, 16, 3111–3118. [Google Scholar]
- Lau, A.; Yang, W.-F.; Li, K.-Y.; Su, Y.-X. Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis. Crit. Rev. Oncol. 2020, 153, 102984. [Google Scholar] [CrossRef]
- Lala, M.; Chirovsky, D.; Cheng, J.D.; Mayawala, K. Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review. Oral Oncol. 2018, 84, 108–120. [Google Scholar] [CrossRef] [PubMed]
- Büntzel, J.; Micke, O. Second-line chemotherapy in head and neck cancer: What should we expect? Expert Rev. Anticancer. Ther. 2009, 9, 269–273. [Google Scholar] [CrossRef]
- Vermorken, J.B.; Mesia, R.; Rivera, F.; Remenar, E.; Kawecki, A.; Rottey, S.; Erfan, J.; Zabolotnyy, D.; Kienzer, H.-R.; Cupissol, D.; et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N. Engl. J. Med. 2008, 359, 1116–1127. [Google Scholar] [CrossRef] [Green Version]
- Perri, F.; Ionna, F.; Longo, F.; Scarpati, G.D.V.; De Angelis, C.; Ottaiano, A.; Botti, G.; Caponigro, F. Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy. Transl. Oncol. 2020, 13, 262–274. [Google Scholar] [CrossRef]
- Ferris, R.L.; Blumenschein, G., Jr.; Fayette, J.; Guigay, J.; Colevas, A.D.; Licitra, L.; Harrington, K.; Kasper, S.; Vokes, E.E.; Even, C.; et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N. Engl. J. Med. 2016, 375, 1856–1867. [Google Scholar] [CrossRef]
- Burtness, B.; Rischin, D.; Greil, R.; Soulières, D.; Tahara, M.; de Castro, G.; Psyrri, A.; Basté, N.; Neupane, P.; Bratland, Å.; et al. Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1–19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis. In Proceedings of the AACR Annual Meeting, Philadelphia, PA, USA, 27–28 April 2020 and 22–24 June 2020. [Google Scholar]
- Burtness, B.; Harrington, K.J.; Greil, R.; Soulières, D.; Tahara, M.; de Castro, G., Jr.; Psyrri, A.; Basté, N.; Neupane, B.; Bratland, A.; et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet 2019, 394, 1915–1928. [Google Scholar] [CrossRef]
- Hecht, M.; Hahn, D.; Wolber, P.; Hautmann, M.G.; Reichert, D.; Weniger, S.; Belka, C.; Bergmann, T.; Göhler, T.; Welslau, M.; et al. Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer. BMC Cancer 2020, 20, 1–11. [Google Scholar] [CrossRef]
- Hellman, S.; Weichselbaum, R.R. Oligometastases. J. Clin. Oncol. 1995, 13, 8–10. [Google Scholar] [CrossRef] [PubMed]
- Beckham, T.H.; Leeman, J.E.; Xie, P.; Li, X.; Goldman, D.A.; Zhang, Z.; Sherman, E.; McBride, S.; Riaz, N.; Lee, N.; et al. Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy. Br. J. Cancer 2019, 121, 897–903. [Google Scholar] [CrossRef] [PubMed]
- Shiono, S.; Kawamura, M.; Satoshi, S.; Okumura, S.; Nakajima, J.; Yoshino, I.; Ikeda, N.; Horio, H.; Akiyama, H.; Kobayashi, K. Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas. Ann. Thorac. Surg. 2009, 88, 856–860. [Google Scholar] [CrossRef] [PubMed]
- Kasperts, N.; Slotman, B.; Leemans, C.; Langendijk, J. A review on re-irradiation for recurrent and second primary head and neck cancer. Oral Oncol. 2005, 41, 225–243. [Google Scholar] [CrossRef]
- Meulemans, J.; Demarsin, H.; Debacker, J.; Batailde, G.; Mennes, T.; Laenen, A.; Goeleven, A.; Neyt, P.; Vanclooster, C.; Vauterin, T.; et al. Functional Outcomes and Complications After Salvage Total Laryngectomy for Residual, Recurrent, and Second Primary Squamous Cell Carcinoma of the Larynx and Hypopharynx: A Multicenter Retrospective Cohort Study. Front. Oncol. 2020, 10. [Google Scholar] [CrossRef]
- Marconi, R.; Strolin, S.; Bossi, G.; Strigari, L. A meta-analysis of the abscopal effect inpreclinical models: Is the biologically effective dose a relevant physical trigger? PLoS ONE 2017, 12, e0171559. [Google Scholar]
- Choi, J.S.; Sansoni, E.R.; Lovin, B.D.; Lindquist, N.R.; Phan, J.; Mayo, L.L.; Ferrarotto, R.; Su, S.Y. Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review. Ann. Otol. Rhinol. Laryngol. 2019, 129, 517–522. [Google Scholar] [CrossRef]
- Zeng, J.; Harris, T.J.; Lim, M.; Drake, C.G.; Tran, P.T. Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses. BioMed Res. Int. 2013, 2013, 1–8. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ionna, F.; Bossi, P.; Guida, A.; Alberti, A.; Muto, P.; Salzano, G.; Ottaiano, A.; Maglitto, F.; Leopardo, D.; De Felice, M.; et al. Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. Cancers 2021, 13, 2371. https://doi.org/10.3390/cancers13102371
Ionna F, Bossi P, Guida A, Alberti A, Muto P, Salzano G, Ottaiano A, Maglitto F, Leopardo D, De Felice M, et al. Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. Cancers. 2021; 13(10):2371. https://doi.org/10.3390/cancers13102371
Chicago/Turabian StyleIonna, Franco, Paolo Bossi, Agostino Guida, Andrea Alberti, Paolo Muto, Giovanni Salzano, Alessandro Ottaiano, Fabio Maglitto, Davide Leopardo, Marco De Felice, and et al. 2021. "Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies" Cancers 13, no. 10: 2371. https://doi.org/10.3390/cancers13102371
APA StyleIonna, F., Bossi, P., Guida, A., Alberti, A., Muto, P., Salzano, G., Ottaiano, A., Maglitto, F., Leopardo, D., De Felice, M., Longo, F., Tafuto, S., Della Vittoria Scarpati, G., & Perri, F. (2021). Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. Cancers, 13(10), 2371. https://doi.org/10.3390/cancers13102371